Equities

Adapthealth Corp

AHCO:NAQ

Adapthealth Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)9.86
  • Today's Change-0.035 / -0.35%
  • Shares traded777.93k
  • 1 Year change+15.94%
  • Beta1.1090
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adapthealth Corp. provides patient-centered, healthcare-at-home solutions, including home medical equipment (HME), medical supplies and related services. The Company is primarily focused on providing sleep therapy equipment, supplies and related services, including CPAP and bi PAP services to individuals suffering from obstructive sleep apnea (OSA); medical devices and supplies to patients for the treatment of diabetes, including continuous glucose monitors (CGM) and insulin pumps; home medical equipment to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. It serves patients annually in all 50 states through its network of approximately 680 locations in 47 states.

  • Revenue in USD (TTM)3.26bn
  • Net income in USD-217.76m
  • Incorporated2017
  • Employees10.70k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CeriBell Inc-100.00bn-100.00bn936.89m----------------0.336------------------------2.14--0.6304--74.47--20.72------
Bioventus Inc555.06m-39.48m950.32m1.03k--6.39--1.71-0.6172-0.61728.681.830.70231.954.73572,227.80-6.47-5.52-9.13-7.2767.0068.25-9.22-10.940.98661.130.6725--0.04459.936.91--23.51--
Owens & Minor, Inc.10.66bn-48.79m952.30m13.70k--1.094.300.0893-0.6346-0.6346139.2711.352.097.2615.86778,172.30-0.95611.32-1.492.0720.7216.48-0.45760.56140.45192.030.68310.7983.801.87-284.47--25.91--
Pulse Biosciences Inc0.00-46.13m1.09bn56.00--13.74-----0.8069-0.80690.001.290.00----0.00-58.03-93.21-62.84-104.99-------12,332.25----0.00---100.00--27.85---15.20--
Artivion Inc384.90m-846.00k1.19bn1.50k--3.8951.813.08-0.0235-0.02359.257.270.48791.685.50256,599.30-0.1079-2.20-0.1242-2.3664.5365.51-0.2211-5.341.331.100.51--12.826.14-60.09--5.13--
BioLife Solutions Inc118.41m-26.44m1.20bn409.00--3.69--10.13-0.5826-1.012.597.040.29871.695.58289,513.40-6.67-13.76-7.37-15.0446.1536.76-22.33-42.991.78-4.030.0614---11.4348.6552.49--86.35--
Establishment Labs Holdings Inc153.07m-70.61m1.21bn933.00--36.83--7.88-2.58-2.585.571.170.55340.79162.51168,580.40-25.53-33.22-31.21-41.1265.0864.73-46.13-43.192.29-4.510.856--2.1321.96-4.38--69.16--
Evolent Health Inc2.46bn-104.23m1.31bn4.70k--1.2590.000.5322-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
STAAR Surgical Co341.22m21.78m1.31bn1.06k60.903.0747.533.850.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Adapthealth Corp3.26bn-217.76m1.33bn10.70k--0.87448.050.4064-1.64-1.6424.2311.270.709621.158.45304,912.50-4.57-4.34-5.14-4.8919.0318.28-6.44-6.470.99512.290.5757--7.73---1,169.99------
Myriad Genetics, Inc.823.60m-116.00m1.41bn2.70k--1.93--1.71-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Alphatec Holdings Inc572.74m-177.87m1.43bn839.00------2.49-1.27-1.274.080.15460.80891.117.73682,644.80-25.12-30.97-32.00-39.4769.4766.02-31.06-46.221.15-3.660.9596--37.4539.38-23.36--67.92--
Inmode Ltd423.75m153.67m1.45bn581.0010.302.139.403.421.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
10X Genomics Inc629.74m-182.55m1.73bn1.26k--2.40--2.75-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
AtriCure Inc447.57m-38.92m1.74bn1.20k--3.75--3.89-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
Data as of Nov 22 2024. Currency figures normalised to Adapthealth Corp's reporting currency: US Dollar USD

Institutional shareholders

43.84%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 202414.98m11.14%
The Vanguard Group, Inc.as of 30 Sep 202412.26m9.12%
Fidelity Management & Research Co. LLCas of 30 Sep 20247.19m5.35%
Reinhart Partners, Inc.as of 30 Sep 20246.20m4.61%
SSgA Funds Management, Inc.as of 30 Sep 20244.12m3.07%
Segall Bryant & Hamill LLCas of 30 Sep 20243.70m2.75%
Millennium Management LLCas of 30 Sep 20243.22m2.39%
Dimensional Fund Advisors LPas of 30 Sep 20242.67m1.99%
Geode Capital Management LLCas of 30 Sep 20242.45m1.82%
Truist Bank (Private Banking)as of 30 Sep 20242.16m1.61%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.